Pharmaceutical Executive: Apr 13, 2015
Casey McDonald asks, is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?
Pharmaceutical Executive: Apr 11, 2015
FDA is under pressure to moderate oversight of pharma advertising and promotion.
Apr 11, 2015
The announcement by UnitedHealth Group of its planned acquisition of pharmacy benefits manager (PBM) Catamaran for $12.8 billion officially puts the pharmaceutical industry on notice that the “war” on drug prices is escalating, writes Michael Griffith.
Apr 06, 2015
That the UK's NHS has struck a deal for a national roll-out of Bexsero, GSK's vaccine for Meningitis B in infants, is good, but it needs to do better, writes Leela Barham.
Apr 01, 2015
Dr. Anuj Gupta explains the potential implications of the GST— or the goods and services tax — on Indian pharma.
Apr 01, 2015
In Europe drug pricing concerns are continuing to invade the hitherto sacrosanct territory of drug development, writes Peter O'Donnell.
Mar 30, 2015
Steve Smith provides an advocates account of last month's Rare Disease Week on Capitol Hill.
Mar 29, 2015
A controversial FDA proposal to alter the process for making changes to approved drug labels has drawn opposition and support in equal measure, writes Jill Wechsler.
Mar 24, 2015
Albert Wertheimer, PhD, MBA, Professor of Pharmaceutical Economics at Temple University and a member of Pharm Exec's Editorial Advisory Board, shows how the simple matter of a drug shortage is not a simple matter at all.
Mar 17, 2015
The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric — combined. It's counterintuitive…if not overwhelming, writes Lisa Barbadora